A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

Active:	Yes
Cancer Type:	Melanoma Unknown Primary	NCT ID:	NCT05933577
Trial Phases:	Phase III	Protocol IDs:	V940-001 (primary) NCI-2023-05647 2023-503652-27-00 V940-001
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp & Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT05933577

Summary

The purpose of this study is to learn if V940 which is an individualized neoantigen
therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab
(MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma.
Researchers want to know if V940 with pembrolizumab is better than receiving
pembrolizumab alone at preventing the cancer from returning.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.